SRR8518268
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COMPLEMENT+0.460
- ALLOGRAFT_REJECTION+0.430
- COAGULATION+0.420
- INFLAMMATORY_RESPONSE+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- IL6_JAK_STAT3_SIGNALING+0.350
- KRAS_SIGNALING_UP+0.340
- PANCREAS_BETA_CELLS+0.320
- XENOBIOTIC_METABOLISM+0.290
- ANGIOGENESIS+0.250
Top 10 suppressed
- MYC_TARGETS_V2-0.700
- E2F_TARGETS-0.650
- G2M_CHECKPOINT-0.630
- MYC_TARGETS_V1-0.630
- UNFOLDED_PROTEIN_RESPONSE-0.470
- DNA_REPAIR-0.400
- MITOTIC_SPINDLE-0.390
- MTORC1_SIGNALING-0.370
- GLYCOLYSIS-0.300
- APICAL_SURFACE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518195 | — | A | 0.916 |
| 2 | SRR2016962 | — | — | 0.906 |
| 3 | TCGA-L4-A4E6-01A-11R-A24H-07 | — | cohortA1 | 0.876 |
| 4 | SRR8518405 | — | A | 0.866 |
| 5 | ERR2598318 | fetal | fetal | 0.865 |
| 6 | SRR2016935 | — | — | 0.863 |
| 7 | SRR5088905 | — | — | 0.862 |
| 8 | d552ba81-1140-4ab6-a14c-659c07e494d0 | — | — | 0.861 |
| 9 | TCGA-49-4505-01A-01R-1206-07 | — | cohortA1 | 0.859 |
| 10 | SRR5088928 | — | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COMPLEMENT | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |